Not Yet RecruitingPhase 4

Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding

672 participantsStarted 2023-10-01

Plain-language summary

Acute Variceal Bleeding (AVB) in patients with liver cirrhosis is a common clinical critical disease. There is little evidence for the effect of proton pump inhibitor (PPI) use in patients with AVB, and there is no study on the efficacy of PPI combined with standard therapy in patients with AVB.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Liver cirrhosis.
✓. The etiology of portal hypertension is cirrhosis.
✓. Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 24 hours.
✓. Be willing to participate in this clinical study, comply with the study requirements and sign the informed consent

Exclusion criteria

✕. non-cirrhotic portal hypertension
✕. the time from admission to endoscopy was more than 24 hours
✕. patients with peptic ulcer or gastroesophageal reflux disease requiring PPI therapy
✕. PPI use for more than 2 weeks before admission
✕. received endoscopic or interventional therapy within the previous 4 weeks
✕. PPI allergy
✕. Chronic renal insufficiency (CKD stage 3-5)
✕. Severe cardiopulmonary dysfunction (such as heart failure grade 3-4, respiratory failure, etc.)

What they're measuring

5-day treatment failure rate

Timeframe: 5 days

Trial details

NCT IDNCT05624229

SponsorWest China Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Upper Gastrointestinal Hemorrhage trials